SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int. 1996; 50: 137391.
  • 2
    Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am. J. Kidney Dis. 1999; 34: 108995.
  • 3
    Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol. Dial. Transplant. 2002; 17 (Suppl 1): 4852.
  • 4
    Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004; 19 (Suppl 2): ii147.
  • 5
    KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 2006; 47: S1145.
  • 6
    Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): Current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol. Dial. Transplant. 2005; 20 (Suppl 3): iii324.
  • 7
    Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50: 16949.
  • 8
    Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in PD patients. Nephrol. Dial. Transplant. 2001; 16:187984.
  • 9
    Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J. Assoc. Physicians India 2003; 51: 17074.
  • 10
    St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994–2002). Am. J. Kidney Dis. 2005; 46: 65060.
  • 11
    Horl WH, Jacobs C, Macdougall IC. European Survey on Anaemia Management (ESAM). Nephrol. Dial. Transplant. 2000; 15: 435.
  • 12
    Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin. Nephrol. 1995; 44: 23840.
  • 13
    Aronoff GR. Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J. Am. Soc. Nephrol. 2004; 15 (Suppl 2): S99106.
  • 14
    Devita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin. Nephrol. 2003; 60: 33540.
  • 15
    Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 2000; 11: 53038.
  • 16
    Roger S. The CARI guidelines. Haematological targets. Iron. Nephrology (Carlton) 2006; 11 (Suppl 1): S21729.
  • 17
    Nissenson AR, Charytan C. Controversies in iron management. Kidney Int. Suppl. 2003; 87: S6471.
  • 18
    Fishbane S. Safety issues with iron sucrose. Am. J. Kidney Dis. 2003; 41: 899.
  • 19
    Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J. Am. Soc. Nephrol. 2007; 18: 97584.
  • 20
    Saltissi D, Sauvage D, Westhuyzen J. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin. Nephrol. 1998; 49: 458.
  • 21
    Macdougall IC, Chandler G, Armstrong A, Breen C, Harchowal J, Cavill J. Characterisation of iron availability from 3 different iron preparations in dialysis patients [Abstract]. J. Am. Soc. Nephrol. 1997; 8: 221.
  • 22
    Chandler G. Intravenous iron hydroxy saccharate: Establishing the optimum dose [Abstract]. J. Am. Soc. Nephrol. 2001; 8: 217.
  • 23
    Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 1996; 28: 52934.
  • 24
    Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am. J. Kidney Dis. 1999; 33: 46470.
  • 25
    Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1: 12934.
  • 26
    Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 221217.
  • 27
    Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int. 1999; 55 (Suppl 69): S616.
  • 28
    Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J. Am. Soc. Nephrol. 1998; 9: 86976.
  • 29
    Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2004; 15: 162332.
  • 30
    Kalantar-Zadeh K, Regidor DL, Mcallister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005; 16: 307080.
  • 31
    Feldman HI, Santanna J, Guo W et al. Iron administration and clinical outcomes in hemodialysis patients. J. Am. Soc. Nephrol. 2002; 13: 73444.
  • 32
    Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899911.
  • 33
    Panichi V, Migliori M, De Pietro S et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002; 91: 594600.
  • 34
    Herzig KA, Purdie DM, Brown AM et al. Is C-reactive protein a useful prognostic marker in PD patients? J. Am. Soc. Nephrol. 2001; 12: 81421.
  • 35
    Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 64858.
  • 36
    Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2000; 35: 46976.
  • 37
    Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am. J. Kidney Dis. 1997; 29: 5658.
  • 38
    Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J. 2001; 47: 825.
  • 39
    Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol. Dial. Transplant. 2002; 17 (Suppl 1): 539.
  • 40
    Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and PD patients. Am. J. Kidney Dis. 1999; 33: 6372.
  • 41
    Park JS, Kim SB. C-reactive protein as a cardiovascular risk factor and its therapeutic implications in end-stage renal disease patients. Nephrology 2003; 8: S4049.
  • 42
    Kaysen GA, Eiserich JP. Characteristics and effects of inflammation in end-stage renal disease. Semin. Dial. 2003; 16: 43846.
  • 43
    Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol. Dial. Transplant. 2002; 17 (Suppl 8):338.
  • 44
    Lopez-Gomez JM, Perez-Flores I, Jofre R et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J. Am. Soc. Nephrol. 2004; 15: 2494501.
  • 45
    Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int. 2004; 66: 242936.
  • 46
    Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol. Dial. Transplant. 2001; 16 (Suppl 7): 258.
  • 47
    Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur. J. Clin. Invest. 2005; 35 (Suppl 3): 325.
  • 48
    Malyszko J, Malyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am. J. Nephrol. 2005; 25: 58690.
  • 49
    Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients – A prospective cross-over study. J. Nephrol. 2004; 17: 693700.
  • 50
    Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol. Dial. Transplant. 2000; 15: 120711.
  • 51
    Ayus JC, Achinger SG. At the peril of dialysis patients: Ignoring the failed transplant. Semin. Dial. 2005; 18: 18084.
  • 52
    Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am. J. Kidney Dis. 2006; 47: 64454.
  • 53
    Kobayashi S, Moriya H, Aso K, Ohtake T. Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int. 2003; 63: 18817.
  • 54
    Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J. 2003; 49: 4225.
  • 55
    Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J. Am. Soc. Nephrol. 2004; 15: 187782.
  • 56
    Navarro JF, Mora C, Garcia J et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand. J. Urol. Nephrol. 1999; 33: 1215.
  • 57
    Kobayashi H, Ono T, Yamamoto N. Removal of high molecular weight substances with large porse size membrane (BK-F). Kidney Dial. 1993; 34: 1547.
  • 58
    Kawano Y, Takaue Y, Kuroda Y, Minkuchi J, Kawashima S. Effect on alleviation of renal anemia by haemodialysis using the high-flux dialyzer (BK-F). Kidney Dial. 1994; 34: 200203.
  • 59
    Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: What is the evidence base? Nephrol. Dial. Transplant. 2003; 18 (Suppl 8): viii2935.
  • 60
    Locatelli F, Andrulli S, Pecchini F et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol. Dial. Transplant. 2000; 15: 1399409.
  • 61
    Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2003; 348: 14914.
  • 62
    Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory PD. Nephron 1990; 56: 2415.
  • 63
    Mcgonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984; 25: 43744.
  • 64
    Opatrny K Jr, Reischig T, Vienken J et al. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif. Organs 2002; 26: 1818.
  • 65
    Keven K, Kutlay S, Nergizoglu G, Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am. J. Kidney Dis. 2003; 41: 12339.
  • 66
    Chan D, Irish A, Dogra G. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton) 2005; 10: 33640.
  • 67
    Yang CC, Hsu SP, Wu MS, Hsu SM, Chien CT. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int. 2006; 69: 70614.
  • 68
    Bernardini J, Nagy M, Piraino B. Pattern of noncompliance with dialysis exchanges in PD patients. Am. J. Kidney Dis. 2000; 35: 110410.
  • 69
    Wazny LD, Stojimirovic BB, Heidenheim P, Blake PG. Factors influencing erythropoietin compliance in PD patients. Am. J. Kidney Dis. 2002; 40: 6238.
  • 70
    Kaveh K, Kimmel PL. Compliance in hemodialysis patients: Multidimensional measures in search of a gold standard. Am. J. Kidney Dis. 2001; 37: 24466.
  • 71
    Santiago GC, Rao TK, Laird NM. Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study. Kidney Int. Suppl. 1983: S95100.
  • 72
    Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N. Engl. J. Med. 1996; 334: 42025.
  • 73
    Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol. Dial. Transplant. 2001; 16: 11114.
  • 74
    Klarenbach S, Heidenheim AP, Leitch R, Lindsay RM. Reduced requirement for erythropoietin with quotidian hemodialysis therapy. ASAIO J. 2002; 48: 5761.
  • 75
    Akmal M, Telfer N, Ansari AN, Massry SG. Erythrocyte survival in chronic renal failure. Role of secondary hyperparathyroidism. J. Clin. Invest. 1985; 76: 16958.
  • 76
    Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin. Dial. 2006; 19: 14651.
  • 77
    Mandolfo S, Malberti F, Farina M et al. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure. Nephrol. Dial. Transplant. 1998; 13: 27089.
  • 78
    Lee CT, Chou FF, Chang HW et al. Effects of parathyroidectomy on iron homeostasis and erythropoiesis in hemodialysis patients with severe hyperparathyroidism. Blood Purif. 2003; 21: 36975.
  • 79
    Neves PL, Trivino J, Casaubon F et al. Elderly patients on chronic hemodialysis with hyperparathyroidism: Increase of hemoglobin level after intravenous calcitriol. Int. Urol. Nephrol. 2006; 38: 1757.
  • 80
    Zachee P, Chew SL, Daelemans R, Lins RL. Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am. J. Nephrol. 1992; 12: 18891.
  • 81
    Suega K, Bakta M, Dharmayudha TG, Lukman JS, Suwitra K. Profile of anemia in chronic renal failure patients: Comparison between predialyzed and dialyzed patients at the Division of Nephrology, Department of Internal Medicine, Sanglah Hospital, Denpasar, Bali, Indonesia. Acta Med. Indones. 2005; 37: 19094.
  • 82
    Schiffl H, Lang SM. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients. Nephrol. Dial. Transplant. 2006; 21: 1337.
  • 83
    Bamgbola OF, Kaskel F. Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr. Nephrol. 2005; 20: 16229.
  • 84
    Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol. Dial. Transplant. 1995; 10 (Suppl 6): 447.
  • 85
    Schreiber BD. Debate forum: Levocarnitine therapy is rational and justified in selected dialysis patients. Blood Purif. 2006; 24: 12839.
  • 86
    Kooistra MP, Struyvenberg A, Van Es A. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991; 57: 1278.
  • 87
    Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muramoto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 1996; 72: 5748.
  • 88
    Handelman GJ. Debate forum: Carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy. Blood Purif. 2006; 24: 14042.
  • 89
    Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of 1-carnitine supplementation in maintenance hemodialysis patients: A systematic review. J. Am. Soc. Nephrol. 2002; 13: 70814.
  • 90
    IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am. J. Kidney Dis. 2001; 37: S182238.
  • 91
    Azizi M, Rousseau A, Ezan E et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 1996; 97: 83944.
  • 92
    Casadevall N. Cellular mechanism of resistance to erythropoietin. Nephrol. Dial. Transplant. 1995; 10 (Suppl 6): 2730.
  • 93
    Kausz AT, Antonsen JE, Hercz G et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am. J. Kidney Dis. 1999; 34: 68893.
  • 94
    Milliner DS, Nebeker HG, Ott SM et al. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann. Intern. Med. 1984; 101: 7759.
  • 95
    Yaqoob M, Ahmad R, Mcclelland P et al. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy. Postgrad. Med. J. 1993; 69: 1248.
  • 96
    Von Bonsdorff M, Sipila R, Pitkanen E. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload. Scand. J. Urol. Nephrol. Suppl. 1990; 131: 4954.
  • 97
    Roger SD, Stewart JH, Harris DC. Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common. Nephron 1991; 58: 336.
  • 98
    Mittelman M. The implications of anemia in multiple myeloma. Clin. Lymphoma 2003; 4 (Suppl 1): S239.
  • 99
    Maisnar V, Chroust K. Treatment of associated anemia in different hematological disorders with epoetin alpha. Neoplasma 2004; 51: 37984.
  • 100
    Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin. Oncol. 1992; 19: 2935.
  • 101
    Ludwig H, Rai K, Blade J et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations. Hematol. J. 2002; 3: 12130.
  • 102
    Baz R, Walker E, Choueiri TK et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol. 2006; 117: 1627.
  • 103
    Rossert J. Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur. J. Clin. Invest. 2005; 35 (Suppl 3): 959.
  • 104
    Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet 2004; 363: 176871.
  • 105
    Woodburn KW, Winslow S, Leuther KK. Hematide, a Peptidic Erythropoiesis Stimulating Agent that Corrects Anaemia Induced by Partial Nephrectomy and Erythropoietin-specific Antibodies in Rats. European Haematology Association Meeting, Stockholm, 2005.
  • 106
    Gallucci MT, Lubrano R, Meloni C et al. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin. Nephrol. 1999; 52: 23945.
  • 107
    Tomson CR, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol. Dial. Transplant. 1992; 7: 81721.
  • 108
    Breen CP, Macdougall IC. Improvement of erythropoietin-resistant anaemia after renal transplantation in patients with homozygous sickle-cell disease. Nephrol. Dial. Transplant. 1998; 13: 294952.
  • 109
    Di Iorio B, Guastaferro P, Bellizzi V. Relationship between resistance to erythropoietin and high anomalous hemoglobin levels in hemodialysis patients with beta-thalassemia minor. Blood Purif. 2003; 21: 37680.
  • 110
    Leighton JA, Goldstein J, Hirota W et al. Obscure gastrointestinal bleeding. Gastrointest. Endosc. 2003; 58: 65055.